TiumBio is gaining in early trading on the 7th on news that it received a decision in the United States to register a patent for a combination therapy of the immuno-oncology candidate "Tosposertib."
At 9:23 a.m. on the 7th, on the KOSDAQ market, TiumBio was trading at 4,825 won, up 520 won (11.90%) from the previous session.
It is interpreted that investor buying is flowing in as TiumBio recently shared news that the combination therapy of Tosposertib completed U.S. patent registration.
The patent, for which a decision was received from U.S. authorities, concerns a method of preventing and treating tumors by combining Tosposertib with at least one of major immune checkpoint inhibitor classes such as anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, and lenvatinib.
It is assessed that the scope of exclusive rights has been secured broadly across the entire class of immune checkpoint inhibitors, not limited only to the combination with pembrolizumab, for which a combination clinical trial has begun. TiumBio said that the combined global sales last year of five representative drugs in the core immune checkpoint inhibitor class, excluding lenvatinib, were about $55 billion (about 75 trillion won), serving as a key pillar of the global anticancer drug market.
The range of applicable diseases has also been greatly expanded. Across various cancer types including melanoma, as well as breast, pancreatic, ovarian, lung, colorectal, liver, biliary tract, prostate, kidney, and head and neck cancers, the rights to the Tosposertib combination therapy were recognized.
In addition to oral administration, it broadly includes multiple routes of administration such as intravenous infusion (IV), subcutaneous injection (SC), and intramuscular injection (IM), and the combination drugs also encompass all methods within the patent scope, including integrated administration in a single formulation or separate formulations, and concurrent, sequential, or individual administration.
The term of the U.S. patent runs through July 2042. If the patent term adjustment (PTA) system is applied, the maximum term of rights could be extended to July 2043.